-
News and Information
- What's happening with GRACE! Check here to see events, partnerships, any new news for our community!
Opportunities and Volunteering
- Click here to see how you can get involved with GRACE!
The GRACE Community
Our Team
What is the Global Resource for Advancing Cancer Education (GRACE)?
The Global Resource for Advancing Cancer Education (GRACE) provides expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care
GRACE is a nonprofit organization that was developed as a means of improving the overall medical care for cancer patients by democratizing cutting edge information on optimal cancer management and providing it directly to patients. We recognized that while there is an overwhelming amount of new information available to physicians, actually more than they could integrate, patients and their families often have a deep interest in their own care and often have the time and motivation to ensure that they are receiving the best treatment possible.
There are already many websites and other resources that provide some information for patients from health care professionals, but we find that they often provide very bland, nonspecific information that says little beyond extreme generalities (i.e., “Chemotherapy is the main treatment for advanced lung cancer. Your doctor may talk with you about this approach.”). And while there are often discussions of specific treatments on patient and caregiver-moderated websites and other resources, the quality of the information is variable: sometimes great, and sometimes suspect. The potential for misinformation to be perpetuated by people not qualified to discuss medical details is a significant problem.
GRACE is the larger nonprofit entity borne of the website OncTalk, which was started in late 2006 by Dr. West as a means of providing detailed information about best practices in lung cancer directly to the general public in an interactive format, from a known source. Since that time, several thousand unique visitors have sought information from the growing collection of posts on a variety of topics in lung cancer and oncology in general. But the idea behind OncTalk was always to scale beyond one physician and a narrow topic. Proving the principle that the barriers between information for physicians and education for patients could be overcome, OncTalk transitioned into the nonprofit company GRACE in order to expand into a broader range of cancer topics while also providing a greater depth of formats for providing educational materials to members. In addition to blog-format interactive software for online information and discussion, GRACE is introducing audio interviews, web-based lecture materials, live programs, podcasts, and live and on-demand, interactive webinars.
The Global Resource for Advancing Cancer Education (GRACE) is a nonprofit organization that has been granted tax-exempt status from the IRS under section 501(c)(3) of the US tax code. Donations are tax-deductible according to current tax law for 501(c)(3) organizations. Our Tax ID is 56-2676328.
For information on how to contribute, please click here.
Featured Content
Join us for this Free Webinar on Saturday, December 14, 2024 8:00 AM - 10:30 AM Pacific, 11 AM - 1:30 PM Eastern This live, virtual, interactive patient education event includes presentations and panel discussions covering general subjects relevant to a diverse range of lung cancers and treatment options and an opportunity to speak with the experts in a Q&A session. Speakers include top medical professionals presenting patient-focused discussions to educate the patient and caregiver communities...
Join us for this Free Webinar on Saturday, December 14, 2024 8:00 AM - 10:30 AM Pacific, 11 AM - 1:30 PM Eastern This live, virtual, interactive patient education event includes presentations and panel discussions covering general subjects relevant to a diverse range of lung cancers and treatment options and an opportunity to speak with the experts in a Q&A session. Speakers include top medical professionals presenting patient-focused discussions to educate the patient and caregiver communities...
Join us for this Free Webinar on Saturday, October 12, 2024 8:00 AM - 10:45 AM Pacific, 11 AM - 1:45 PM Eastern This live, virtual, interactive patient education event includes presentations and panel discussions covering general subjects relevant to a diverse range of blood cancers and treatment options and an opportunity to speak with the experts in a Q&A session. Speakers include top medical professionals presenting patient-focused discussions to educate the patient and caregiver communities...
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Registration is now open! Join us for the annual 2024 Blood Cancers OncTalk! Register Now! This live, virtual, interactive patient education event includes presentations and panel discussions covering general subjects relevant to a diverse range of blood cancers and treatment options, as well as an opportunity to speak with the experts in a Q&A session. Speakers includes top medical professionals presenting patient-focused discussions to educate the patient and caregiver communities to become...
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...